

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ :	A2	(11) International Publication Number: WO 88/00974
C12N 15/00, G01N 33/569 A61K 39/04		(43) International Publication Date: 11 February 1988 (11.02.88)

(21) International Application Number: PCT/US87/01825

(22) International Filing Date: 28 July 1987 (28.07.87)

(31) Priority Application Number: 892,095

(32) Priority Date: 31 July 1986 (31.07.86)

(33) Priority Country: US

(71) Applicant: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH [US/US]; Nine Cambridge Center, Cambridge, MA 02142 (US).

(72) Inventor: YOUNG, Richard, A. ; 11 Sussex Road, Winchester, MA 01890 (US).

(74) Agents: GRANAHAN, Patricia et al.; Hamilton, Brook, Smith & Reynolds, Two Militia Drive, Lexington, MA 02173 (US).

(81) Designated States: AT (European patent), AU, BE (European patent), BR, CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: GENES ENCODING ANTIGENS OF M. LEPRAE

(57) Abstract

Genes encoding five immunodeterminant protein antigens of the leprosy parasite *Mycobacterium leprae* have been isolated. The gene encoding the *M. leprae* 65kD antigen was sequenced and a lambda gt11 gene sublibrary was constructed with fragments of the gene. Recombinant DNA clones producing specific antigenic determinants were isolated using monoclonal antibodies and the sequences of their insert DNAs were determined with a rapid primer extension method. Amino acid sequences for six different epitopes of the *M. leprae* protein were elucidated. A peptide containing sequences for one of these epitopes, which is unique to *M. leprae*, was synthesized and shown to bind the appropriate monoclonal antibody. The approach described here can be used to elucidate rapidly protein epitopes that are recognized by antibodies or T cells. In addition, the well-characterized *M. leprae* antigens can be used in prevention, diagnosis and treatment of leprosy.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT Austria	FR France	ML Mali
AU Australia	GA Gabon	MR Mauritania
BB Barbados	GB United Kingdom	MW Malawi
BE Belgium	HU Hungary	NL Netherlands
BG Bulgaria	IT Italy	NO Norway
BJ Benin	JP Japan	RO Romania
BR Brazil	KP Democratic People's Republic of Korea	SD Sudan
CF Central African Republic	KR Republic of Korea	SE Sweden
CG Congo	LI Liechtenstein	SN Senegal
CH Switzerland	LK Sri Lanka	SU Soviet Union
CM Cameroon	LU Luxembourg	TD Chad
DE Germany, Federal Republic of	MC Monaco	TG Togo
DK Denmark	MG Madagascar	US United States of America
FI Finland		

-1-

Genes Encoding Antigens of *M. leprae*

Description

Background

Leprosy is a chronic infectious disease
5 afflicting millions of people worldwide. The overwhelming majority of leprosy cases occur in Third World countries. Approximately 3000 leprosy cases now exist in the United States and an average of 225 new cases are reported annually, almost all
10 in recent immigrants from areas where leprosy is endemic.

The disease is caused by the obligate intra-cellular parasite Mycobacterium leprae (*M. leprae*), which is found in monocytes, macrophages, epithelial
15 cells and, occasionally, peripheral nerve Schwann cells. The mechanism by which *M. leprae* is transmitted is as yet unknown and the time elapsing between infection with the organism and appearance of clinical symptoms can be as long as 10 years,
20 during which time many others can unknowingly become infected.

-2-

Leprosy is a disease which presents a spectrum of diverse clinical and immunological manifestations. At one end of the spectrum are tuberculoid leprosy patients, who develop high levels of specific cell-mediated immunity, which ultimately kills and clears the bacilli in the tissues. Immunohistochemical studies have identified the predominant infiltrating lymphocytes as T4 helper cells. Peripheral nerve damage occurs concomitant with clearing of the bacilli in tuberculoid leprosy, and is thought to be immunologically mediated.

At the opposite end of the spectrum, lepromatous patients exhibit a selective unresponsiveness to antigens of M. leprae and the organisms often multiply to extraordinary numbers (e.g., $10^{10}/\text{cm}^2$ skin). Infiltrating lymphocytes are predominately of the T8 suppressor type. Peripheral nerve damage also occurs in lepromatous leprosy, although the mechanism of the damage is not clear. The majority of leprosy patients fall between these two extremes in the spectrum and are classified as borderline tuberculoid, borderline, or borderline lepromatous.

Because M. leprae attacks the nerve cells of the skin and peripheral nervous system, a loss of sensation and, in some cases, loss of control over muscles occurs in the extremities. As a result, leprosy victims often do not feel pain, and injuries to hands, arms, legs and feet are not noticed and

-3-

frequently go untreated. Such wounds become infected; formation of scar tissue and scabs follows. Repeated injury results in gradual deformation and destruction of tissues.

5 A method of detecting the disease at an early stage would make it possible to screen populations in areas where the disease is common and begin treatment at an early stage in those affected, thus preventing nerve damage and deformity in the affected individual and limiting its transmission to others. Such a method is not available and diagnosis is presently delayed until clinical signs of the disease appear. Treatment of leprosy patients is not highly successful, particularly because M.
10 leprae is becoming resistant to dapsone, the most widely used anti-leprosy drug. As many as 50 percent of new leprosy patients in some Asian clinics have drug-resistant leprosy.

As with other intracellular parasites, protective immunity against M. leprae is dependent on T cells and cell mediated immunity. Bloom, B.R. and T. Godal, Review of Infectious Diseases, 5:765-780 (1983). The human immune response to M. leprae has been shown to involve both T_4 and T_8 cells, which
20 are thought to be involved in T cell help and T cell suppression, respectively. Little is known about the importance of individual M. leprae antigens for immune protection and/or suppression. It has been shown that T_4 cells from sensitized individuals are
25 stimulated in vitro by crude M. leprae protein
30

-4-

preparations containing five of the most abundant polypeptides in M. leprae (e.g., five protein antigens which are 65kD, 36kD, 23kD, 18kD and 12kD in molecular weight). In contrast, a pure phenolic 5 glycolipid from M. leprae can activate human T_g cells to suppress a mitogenic response in vitro.
Mehra, V. et al., Nature, 308:194 (1984).

At present, there is insufficient knowledge of leprosy and the causative organism, particularly in 10 terms of an understanding of the contribution of the components of M. leprae to protective immunity. In addition, effective, specific and reliable means of diagnosing, preventing and controlling the disease are unavailable.

15 Summary of the Invention

Genes encoding immunodominant protein antigens of the leprosy bacillus Mycobacterium leprae (M. leprae) have been isolated from a recombinant DNA expression library of M. leprae DNA. In particular, 20 genes encoding the five most immunodominant protein antigens of the leprosy bacillus (i.e., those M. leprae proteins of molecular weight 65,000 daltons (65kD), 36kD, 28kD, 18kD and 12kD) have been isolated by probing a lambda gt11 expression library of 25 M. leprae DNA with monoclonal antibodies directed against M. leprae specific antigens. Recombinant DNA clones producing the specific antigenic determinants recognized by the monoclonal antibodies were also isolated in this way and the sequences of

-5-

their insert DNAs were determined with a rapid primer extension method. Amino acid sequences for six different epitopes of the 65kD M. leprae protein were deduced. One of these epitopes is unique to M. leprae; a peptide having the amino acid sequence of this epitope was synthesized and shown to bind the appropriate monoclonal antibody.

As a result, well-characterized M. leprae antigens are available which are useful in the prevention, diagnosis and treatment of leprosy. They can be used, for example, in the development of highly specific serological tests for screening populations for individuals producing antibodies to M. leprae, in the development of vaccines against the disease and in the assessment of the efficacy of treatment of infected individuals.

Brief Description of the Drawings

Figure 1 illustrates the nucleotide sequence of clone Y3178 insert DNA containing the M. leprae 65kD antigen gene. The deduced amino acid sequence is shown above the nucleotide sequence. The epitope containing sequences are underlined.

Figure 2 illustrates arrays of antigen from M. leprae recombinant DNA clones probed with individual monoclonal antibodies.

Figure 3 illustrates restriction maps of M. leprae DNA.

Figure 4 illustrates the result of direct sequencing of lambda gt11 recombinant M. leprae DNA.

-6-

Figure 5 is an epitope map of the M. leprae 65kD antigen. The horizontal line at the bottom represents the Y3178 insert DNA; the open box represents the 65kD antigen open reading frame. The 5 thin horizontal lines represent the extents of insert DNA fragments from Y3178 subclones. The vertical shaded regions indicate the extent of each epitope coding sequence as defined by the minimum overlap among clones that produces a positive signal 10 with an antibody. The insert end points and the antibody binding data for each DNA clone are tabulated at the right. ~ indicates that the nucleotide position was estimated from DNA fragment length data and * indicates that clone Y3211 contains a fragment 15 of lambda gt11 DNA inserted with the M. leprae DNA.

Detailed Description of the Invention

The invention described herein is based on the isolation of genes encoding protein antigens of the leprosy parasite M. leprae. In particular, it is 20 based on the isolation, using monoclonal antibodies directed against M. leprae specific antigens, of genes encoding the five most immunodominant protein antigens of the leprosy bacillus. Immunodominant protein antigens are those antigens against which 25 the immune system directs a significant portion of its response. Genes encoding M. leprae antigens of molecular weight 65,000 daltons (65kD), 36kD, 28kD, 18kD and 12kD were isolated in this manner.

The gene encoding the 65kD antigen of M. leprae

-7-

has been sequenced; its nucleotide sequence and the deduced amino acid sequence of the product it encodes are shown in Figure 1. A sublibrary was constructed with fragments of the gene encoding the 5 65 kD antigen. Using the recombinant DNA strategy described in detail below, expression of epitope-coding sequences by individual recombinant bacteriophage was detected, DNA clones of interest were isolated and their nucleotide sequences 10 determined. Using this approach, it has been possible to define epitopes encoded by the gene for the 65kD protein antigen of M. leprae. The same strategy can, of course, be used to define epitopes encoded by genes for other protein antigens of M. 15 leprae and to define other epitopes recognized by antibodies or T cells. The 65 kD antigen is immunologically relevant in other medically important mycobacteria (e.g., M. tuberculosis and BCG) as well as in M. leprae and contains at least 20 six different epitopes, one of which has been shown to be unique to M. leprae. The other epitopes are shared with the 65kD proteins of other mycobacteria.

As a result of the work described herein, well-characterized M. leprae antigens are available 25 and it is possible to address problems associated with the prevention, diagnosis and treatment of leprosy. For example, M. leprae specific antigenic determinants can be used to develop highly specific serological tests. Such tests are useful in screening populations (e.g., in areas of the world where 30

-8-

leprosy is endemic) for individuals producing antibodies to M. leprae-specific antigenic determinants; in monitoring the development of active disease in individuals and in assessing the efficacy 5 of treatment. As a result, early diagnosis of leprosy will be feasible, making it possible to institute treatment in the early stages of the disease. This, in turn, makes it possible to reduce the likelihood of transmission of the organism from 10 an infected individual (who previously would have remained an undiagnosed case for several years) and to limit the extent of deformity occurring in such an individual.

As a result of the work described, it is also 15 possible to determine which segment(s) of the M. leprae antigen is recognized by M. leprae specific T cells. A mixture of peptides recognized by helper T cells can then provide a specific skin test antigen useful in assessing the immunological status 20 (delayed hypersensitivity) of infected individuals and those with whom they come in contact. This specific skin test antigen is useful in evaluating rapidly the immunological efficacy of anti-leprosy vaccines being developed. Assessment of the protective 25 efficacy of an anti-leprosy vaccine using presently available methods is a lengthy process because of the very long incubation period of the disease. Specific skin tests for delayed hypersensitivity as described herein, however, allow 30 relatively rapid preliminary evaluation of new vaccines.

-9-

It is reasonable to expect that the products encoded by M. leprae genes, particularly those shown to be recognized by helper T cells, are themselves immunogenic and thus useful components of vaccines
5 against leprosy. These products include proteins and portions of such proteins (e.g., polypeptides and peptides). For example, one approach to vaccine development is the introduction of genes encoding products which provide protection into recombinant
10 vaccine vectors, such as vaccinia virus or bacteria (e.g., cultivatable mycobacteria), thus providing a vaccine capable of engendering long-lasting cell-mediated immunity. The genes encoding five immunodeterminant protein antigens of the leprosy
15 bacillus, described herein, are useful for that purpose; the gene encoding the 65kD antigen, or a portion of that gene, is particularly valuable in vaccine construction.

Isolation and characterization of genes encoding immunogenic protein antigens of M. leprae are described below, as are uses of the genes and their encoded products. The description which follows is of the two-step process which was used. In the first step, genes encoding five immunodeterminant
25 protein antigens of M. leprae were isolated from a recombinant DNA expression library of M. leprae DNA. In the second step, a recombinant DNA expression strategy was used to deduce the amino acid sequences of six different antigenic determinants in the 65kD
30 M. leprae protein.

-10-

I. Isolation and Characterization of Genes Encoding Immunogenic Protein Antigens of M. leprae
A. Construction of a recombinant DNA expression library of M. leprae DNA

5 A recombinant DNA expression library of M. leprae DNA was constructed using lambda gt11, a bacteriophage vector capable of driving the expression of foreign insert DNA with E. coli transcription and translation signals. Lambda gt11 expresses
10 the insert DNA as a fusion protein connected to the E. coli Beta-galactosidase polypeptide. The fusion protein approach assures that the foreign sequence will be efficiently transcribed and translated in E. coli. To increase the likelihood that all possible
15 foreign coding sequences would be expressed in E. coli, an approach previously used successfully in isolating M. tuberculosis genes was used. This approach is described by R.A. Young et al. in Proceedings of the National Academy of Sciences,
20 U.S.A., 82:2583-2587 (1985), the teachings of which are incorporated herein by reference.

M. leprae was purified from an armadillo that had been inoculated with bacillus from a single human patient. DNA was purified from the bacillus
25 and was mechanically sheared to produce fragments 1-7 kilobases (kb) in size. EcoRI linkers were added to the ends of the DNA fragments to allow insertion at the unique EcoRI site of lambda gt11. The ligated recombinant DNA was packaged into phage heads and this material was used to infect E. coli cells. Huynh, T. et al., in DNA Cloning Techniques: A Practicing Approach, (D. Glover, ed.) IRL, Press,

-11-

Oxford, 49-78 (1985). The aim of this approach was to generate DNA fragments with random endpoints throughout the foreign genome and to produce recombinant phage in sufficient numbers that insert 5 endpoints occurred at each base pair in the pathogen genome. This strategy should ensure that all coding sequences are inserted in the correct transcriptional orientation and translational frame to be expressed as a fusion protein with the 10 Beta-galactosidase encoded in lambda gt11.

The M. leprae DNA library constructed in this manner contained 2.5×10^6 individual recombinant phage. This library was amplified in E. coli Y1088 by producing a plate stock whose titre was 2×10^{11} 15 PFU (plaque-forming units) ml⁻¹. The amplified library consisted of 25% recombinants whose foreign DNA insert lengths averaged 2 kb, as determined by DNA restriction endonuclease analysis of 25 independent phage clones. The M. leprae genome 20 consists of approximately 10^6 base pairs (bp), and, therefore, it is likely that this library comprehensively represents the DNA of the bacillus.

B. Isolation of recombinant DNA clones encoding M. leprae protein antigens

25 Monoclonal antibodies were produced in mice immunized with intact or crude extracts of armadillo-derived, purified M. leprae Ivanyi, J. et al., in Monoclonal Antibodies Against Bacteria (A.J.L. Macario and E.C. Macario) Academic Press 30 (1984); Gillis, T.P. and T.M. Buchanan, Infection

-12-

and Immunity, 37:172 (1982); Coates, A.R.M. et al., Lancet, ii:167 (1981); Young, D.B. et al., Clinical Experiments in Immunology, 60:546-552 (1985); Engers, H. et al., Infection and Immunity, 48: 5 603-605 (1985). The sizes of the antigens to which the antibodies bind are shown in Table 1; all of the antibodies are IgG1.

Table 1 Monoclonal Antibodies Used to Isolate M. leprae Genes

		<u>M. leprae</u>
	<u>Antibody</u>	<u>Antigen</u>
10	MLIIC8	65kD
	MLIIIC8	65kD
	Y1-2	65kD
15	MLIIH9	65kD
	MLIIIIE9	65kD
	C1-1	65kD
	ML-30	65kD
20	F47 CL9.1	36kD
	SA1.D2D	28kD
	SA1.B11H	28kD
	L7-15	18kD
	ML-06	12kD

The antibodies directed against the antigen of 25 molecular weight 65,000 (65kD) were pooled at approximately 1:200 dilution and used to probe 10^6 plaques (0.25×10^6 recombinant plaques) according to protocols described previously. Young, R.A. et al., in Genetic Engineering: Principles and Techniques

-13-

(J. Setlow and A. Hollaender, ed.) 7:29-41, Plenum Press (1985); Young, R.A. et al., Proceedings of the National Academy of Sciences, U.S.A., 82:2583-2587 (1985). Seventeen plaques produced signals; 15 of 5 these were successfully purified to homogeneity in one or two successive rescreens with the antibody pool.

Recombinant DNA clones isolated in this manner were then arrayed and probed with each of the 10 monoclonal antibodies individually. Figure 2 shows the results obtained with six of the seven anti-bodies directed against the 65 kD antigen.

The recombinant DNA clones were probed with the 15 monoclonal antibodies in the following manner. Drops containing about 10^4 PFU each of 15 cloned lambda gt11 recombinants were arrayed on lawns of E. coli Y1090. The phage were grown and the antigens blotted and probed with individual monoclonal 20 antibodies at about 1:200 dilution. The monoclonal antibodies used were: a, MLIIIC8; b, MLIIIIC8; c, MLIIIE9; d, MLIIH9; e, Y1-2; and f, C1-1. The recombinant DNA clones are coded in section g of 25 Figure 2: 1, Y3159; 2, Y3160; 3, Y3161; 4, Y3162; 5, Y3165; 6, Y3166; 7, Y3170; 8, Y3171; 9, Y3172; 10, Y3173; 11, Y3174; 12, Y3175; 13, Y3176; 14, Y3177; 15, Y3178; 16, lambda gt11 (this phage plaque 30 produced the background signal for each monoclonal antibody). All seven monoclonal antibodies, each directed against a different epitope, were capable of recognizing antigen produced in E. coli. At

-14-

least four different signal patterns were observed in the array of clones. Antibodies MLIIIC8, MLIIIIC8 and MLIIIE9 (Figure 2a, b and c, respectively) produced three distinct patterns. A fourth pattern 5 was generated by antibodies MLIIH9, Y1-2 and C1-1 (Figure 2d, e and f, respectively). Antibody ML-30, directed against an epitope shared with E. coli, produced strong signals with all clones, generating a poorly discernible pattern. There was 10 considerable variation in the number of different epitopes produced by each clone, as evidenced by their reaction with different monoclonal antibodies. While some clones produced antigen that was recognized by only one antibody (for example, clone 13 in 15 Figure 2), and one of the clones produced antigen recognized by all seven antibodies (clone 15), most clones produced antigen that was bound by some intermediate number of antibodies.

Recombinant DNA clones were also isolated and 20 characterized with antibodies directed against the 36kD, 28kD, 18kD and 12kD antigens. Approximately 10^6 lambda gt11 plaques were screened with a pool of these monoclonal antibodies. Eleven plaques that produced signals were purified to homogeneity. 25 Clones were arrayed as in Figure 2 and probed with each of the individual antibodies that comprised the pool. The anti-36kD, 28kD, 18kD and 12kD antibodies produced signals with 1, 4, 4 and 2 recombinant clones, respectively.

-15-

C. Restriction mapping of isolated M. leprae
DNA

The insert DNAs of all the recombinant DNA clones isolated using these monoclonal antibodies were mapped with restriction endonucleases. Lambda DNA was prepared from phage plate stocks according to previously described methods. Davis, R.W. et al., Advanced Bacterial Genetics, Cold Spring Harbor Laboratory (1980). Figure 3 shows the genomic DNA restriction maps deduced for genes encoding each of the five antigens of interest and illustrates how each of the cloned DNAs aligns with that map. In Figure 3, A represents SacI; B, BglIII; E, EcoRI; H, HindIII; K, KpnI; M, BamHI; P, Pvul; S, SalI; and X, XhoI. All clones isolated with monoclonal antibodies directed against any single antigen appear to align with a single genomic DNA segment. For example, the insert DNAs of the 12 recombinant clones isolated with the seven different anti-65kD monoclonal antibodies overlap sufficiently to allow the construction of a unique genomic DNA restriction map with which all clones align unambiguously. This result indicates that all the anti 65-kD antibodies recognize epitopes encoded in a single DNA locus, presumably in a single gene. Similarly, the multiple clones isolated with the anti-28kD, 18kD or 12kD antibodies produced overlapping restriction maps.

One concern with the approach used here is that some recombinant clones may be isolated not because

-16-

they express the protein of interest, but because they express an unrelated polypeptide containing a similar or identical immunological determinant.

However, when multiple recombinant DNA clones were
5 isolated by using a single monoclonal antibody, all contained overlapping DNA; this suggests that each of the epitopes of interest is encoded by a single genomic DNA segment.

10 II. Determination of the amino acid sequence of specific antigenic determinants in M. leprae protein

An efficient recombinant DNA strategy was used to deduce the amino acid sequences that comprise specific antigenic determinants in M. leprae protein.
15 (Antigenic determinants, or epitopes, are the specific segments of antigens that are recognized by antibodies or T cells.) The strategy involves isolating a DNA clone that encodes the entire antigen of interest, determining its nucleotide sequence, and constructing a sublibrary containing fragments of the gene with random end points in the bacteriophage expression vector lambda gt11. Young,
20 R.A. and R.W. Davis, Science, 222:778-782 (1983). The expression of epitope coding sequences by individual recombinant bacteriophage is detected
25 with monoclonal antibody probes and the appropriate DNA clones isolated. The precise nucleotide sequences of the cloned DNA fragments are determined by using primer-directed DNA sequence analysis. The

-17-

DNA sequence encoding the epitope is attributed to sequences that are shared by multiple antibody-positive recombinant clones.

The use of this approach to define epitopes 5 encoded within the gene for the 65 kD protein antigen of Mycobacterium leprae is described below. However, it can be used in a similar manner to define epitopes encoded by other M. leprae genes and, more generally, to elucidate rapidly other 10 protein epitopes that are recognized by antibodies or T cells.

There are several reasons for the selection of the 65kD antigen for detailed study. First, it is one of the major immunologically relevant proteins 15 in a variety of medically important mycobacteria, including Mycobacterium leprae, Mycobacterium tuberculosis and BCG. Gillis, T.P. and T.M. Buchanan, Infections and Immunity, 37:172-178 (1982); Gillis, T.P. et al., Infections and 20 Immunity, 49:371-377 (1985). Antibodies and T cells that recognize the 65 kD antigen can be detected in patients with leprosy or tuberculosis. Second, the antigen contains at least 6 different epitopes that can be distinguished with monoclonal antibodies in 25 competitive inhibition radioimmunoassays. Engers, H. et al., Infections and Immunity, 48:603-605 (1985). One of these epitopes is unique to M. leprae; the remainder are shared with the 65 kD proteins from a number of other mycobacteria.

-18-

The first step in this approach involved defining the M. leprae gene. A lambda gt11 Myco-bacterium leprae recombinant DNA expression library had been constructed and screened with a pool of 5 monoclonal antibodies, as described above, to isolate DNA clones that encode 6 different epitopes within the 65 kD antigen. These monoclonal antibodies, (listed in Table 1) are C1.1, IIH9, IIIE9, IIC8, T2.3 and IIIC8; they are from murine 10 hybridomas obtained by fusion of spleen cells of mice immunized with intact or sonicated, armadillo-derived M. leprae. Recombinant phage plaques that produced signals with these antibodies were purified to homogeneity and their insert DNAs mapped with 15 restriction endonucleases. The recombinant clones that were positive with the pooled antibodies were probed with each of the six monoclonal antibodies in order to identify a clone likely to contain the entire coding sequence for the 65 kD antigen. All 20 of the recombinant phage from the first screen produced signals with one or more antibodies; one (Y3178) produced signals with all six antibodies. The response of the clone designated Y3178 indicated that it contained DNA coding for all of the known 25 65kD epitopes and might therefore contain the entire gene. The fact that all of the monoclonal antibodies used in this study could bind antigen produced by recombinant phage in E. coli prompted further investigation of the nature of the six 30 epitopes in the 65 kD antigen.

-19-

A lambda gt11 gene sublibrary was constructed using the 3.6 kb EcoRI insert DNA fragment of the lambda gt11 clone Y3178. The DNA fragment was isolated by agarose gel electrophoresis and digested 5 with DNaseI (1 ng DNaseI/10ug DNA/ml) in a buffer containing 20 mM tris-HCl (pH 7.5), 1.5 mM MnCl₂, and 100 ug/ml BSA at 24°C for 10-30' to produce short random fragments. The DNA was fractionated on a 1% agarose gel and fragments of 250-1000 bp were 10 isolated and purified. These DNA fragments were end repaired by treatment with T4 DNA polymerase in the presence of dNTPs and then ligated to phosphorylated EcoRI linkers (Collaborative Genetics). This material was digested with EcoRI, heat inactivated 15 at 70°C for 5', and fractionated on a Bio-Rad P60 column to remove unligated linkers. The linker DNA fragments were further purified on an agarose gel from which they were eluted, phenol extracted and ethanol precipitated. The EcoRI-linkered DNA 20 fragments were ligated onto phosphatase-treated lambda gt11 arms (Promega Biotec). The ligated DNA was packaged into lambda phage heads and the resultant recombinant phage were amplified on E. coli Y1090. The library was screened with individual 25 monoclonal antibodies and recombinant clones were isolated as described by Young and co-workers in Young, R.A. et al., Proceedings of the National Academy of Sciences, USA, 82:2583-1587 (1985), the teachings of which are incorporated herein by reference.

-20-

Sequence analysis of DNA from recombinant clone Y3178 was carried out. The DNA was prepared from CsCl purified phage plate stocks and was sequenced by the dideoxy termination method of Sanger et al.

- 5 Huynh, T. et al., DNA Cloning Techniques: A Practical Approach, Vol. 1, (D. Glover, ed.) IRL Press, Oxford, 49-78 (1985); Sanger, F. et al., Journal of Molecular Biology, 143:161-178 (1980). The sequence of both DNA strands was determined and analyzed
10 using the computer programs of Staden. Staden, R., Nucleic Acids Research, 10:4731 (1982).

Direct sequence analysis of DNA insert end-points in lambda gt11 was also carried out by the following methods. Recombinant DNA was isolated
15 from phage purified by CsCl block gradient centrifugation. Huynh, T. et al., in: DNA Cloning Techniques: A Practical Approach, Vol. 1: (D. Glover, ed.) IRL Press, Oxford, 49-78 (1985). DNA (1-5 ug) was digested with the restriction
20 endonucleases KpnI and SacI, phenol extracted, ethanol precipitated and resuspended in 20 ul water. The DNA was denatured by adding 2 ul of 2M NaOH and 2mM EDTA; the resulting solution was incubated for 10 minutes at 37°C. The solution was neutralized
25 with 6.5 ul of 3M sodium acetate (pH 5.2), 6.5 ul water was added and the DNA was ethanol precipitated and resuspended in 10 ul water. To the DNA was added 1 ul of 10 ug.ml DNA primer and 1.5 ul sequencing buffer (75 mM tris HCl, pH 7.5, 75 mM

-21-

DTT, 50 mM MgCl₂). The DNA was incubated at 50°C for 15'. The two primers used (New England Biolabs) were complementary to lacZ sequences adjacent the EcoRI site in lambda gt11; the sequence of the 5 "forward primer" was GGTGGCGACGACTCCTGGAGCCCC, that of the "reverse" primer was TTGACACCAGACCAACTGGTAATG. Primer extension and dideoxy termination reactions were performed immediately after the annealing step as described by 10 Sanger et al. Sanger, F. et al., Journal of Molecular Biology, 143:161-178 (1980). The products were subjected to electrophoresis on an 8% polyacrylamide-8M urea gel.

The determination of the DNA sequence of the 15 3.6kb insert of clone Y3178 (Figure 1) permitted the elucidation of the amino acid sequence of the 65kD antigen. In Figure 1, nucleotides are numbered from the left end of the Y3178 insert DNA. The deduced amino acid sequence is given above the nucleotide 20 sequence. The first translation initiation codon in the open reading frame is a GUG at nucleotide 66, which predicts a 61,856 dalton polypeptide. This is in good agreement with the estimated molecular weight of 65,000 daltons. The first AUG in the open 25 reading frame occurs at nucleotide 207; a polypeptide initiating at this position would have a molecular weight of 56,686 daltons. The antigen of interest appears on SDS polyacrylamide gels as a doublet migrating with an apparent molecular weight 30 of approximately 55-65,000 daltons (55-65kD). Thus,

-22-

translation of the antigen may initiate at both the GUG and the AUG codons, producing the two polypeptides observed. The epitope-containing sequences are underlined.

5 The DNA sequence also indicates that the M. leprae antigen is not expressed as a B-galactosidase fusion protein from the recombinant phage Y3178 in E. coli, suggesting that E. coli may correctly utilize the M. leprae transcription and translation
10 start sites in this gene.

The epitope coding sequences within the 65kD antigen gene were also defined. They were mapped precisely by constructing and screening the lambda gt11 gene sublibrary (described above) that contained small random DNA fragments from the 3.6 kb Y3178 DNA insert. The aim in making the library was to produce recombinant phage in sufficient numbers to obtain DNA insert end points at each base pair in the 65 kD antigen gene, with the result that all
15 possible overlapping segments of the coding sequence were expressed. DNA fragments with random endpoints were generated by digestion of the Y3178 EcoRI insert fragment with DNase I as described above.
20 DNA fragments of 250-1000 base pairs were inserted into lambda gt11 arms, the recombinant DNA was packaged into lambda phage heads and the material was plated on E. coli strain Y1090. A library of
25 10^5 individual phage was obtained of which 98% contained foreign DNA.

30 The Y3178 sublibrary was screened with each of

-23-

the six monoclonal antibodies that were initially used to probe the lambda gt11 M. leprae genomic DNA library. Approximately 500 recombinant plaques were screened and about 10 clones were isolated with each antibody using techniques described previously.

Young , R.A. et al., Proceedings of the National Academy of Sciences, USA, 82:2583-2587 (1985). A total of 54 clones were purified to homogeneity.

The limits of the sequences that encode each epitope were defined by subjecting the recombinant clones to three types of analysis. First, all of the clones were tested for their ability to express each of the six different epitopes. Second, the sequences of the DNA insert endpoints were determined for each clone. Single-stranded DNA primers, complementary to lambda gt11 DNA sequences on one side or the other of the EcoRI site, were hybridized to the recombinant phage DNAs and elongated with DNA polymerase using the dideoxy chain termination sequencing method of Sanger et al. (Figure 4). Sequences of insert DNA endpoints were determined for 40 of the lambda gt11 subclones. All but 2 of these recombinant DNA clones contained insert DNAs whose transcriptional orientations and translational frames predict inframe B-galactosidase fusion proteins. The insert DNAs of clones Y3201 and Y3198 were oriented opposite the others, indicating that these foreign DNA fragments are expressed independent of lacZ gene expression signals.

-24-

Third, the recombinant subclones were characterized by restriction digests to ascertain whether they contained multiple inserts or rearranged insert DNA, either of which could complicate the interpretation of the data. DNA from each of the clones was digested with the restriction endonuclease EcoRI and was subjected to agarose gel electrophoresis to determine the number and sizes of inserted DNA fragments. By this analysis, it was determined that 14 of the clones contained multiple inserts. Of these, 11 were excluded from further study because the endpoints of each of their multiple inserts could not be determined precisely. All of the remaining subclones contained insert DNAs whose sequenced endpoints predict a DNA fragment length that agreed with the size determined by agarose gel electrophoresis. Thus, for a total of 29 individual subclones, the number and type of epitopes expressed could be correlated with the size and endpoint sequence of insert DNA (Figure 5).

The amino acid sequences containing the six epitopes of interest were deduced from the data in Figure 5 and are summarized in Figure 1. The circled letters in Figure 1 designate antigenic determinants for the monoclonal antibodies C1.1(A), MLIIH9(B), MLIIIIE9(C), MLIIC8(D), T2.3(E) and MLIIIC8,(F). The amino acid sequence containing an epitope is defined here as the minimum coding sequence shared by all subclones that produce positive signals with a particular antibody. Since

-25-

the epitope lies within the amino acid sequences shared by signal-producing clones, the definition of the boundaries of an epitope should improve as larger numbers of recombinant clones are analyzed.

- 5 Each of the six epitopes investigated here was determined to lie within 13 to 35 amino acids. However, the minimum coding sequence will not necessarily fall within this range (e.g., it can be fewer than 13 amino acids or more than 35 amino acids).

10

Assessment of the Technique used to Elucidate Antigenic Determinants

One of the antigenic determinants elucidated with this approach, that recognized by the monoclonal antibody MLIIIIE9, is unique to M. leprae.

- 15 Enger, H. et al., Infections and Immunology, 48:603-605 (1985). This 15 amino acid peptide was synthesized and tested by ELISA to determine whether it is bound by MLIIIIE9. Of the six anti-65 kD antibodies tested, only MLIIIIE9 bound to this
- 20 peptide. Using ELISA plates coated with 20 ug/ml of BSA-conjugated peptide, the midpoint of the titration occurred at a 1 in 30,000 dilution of ascites. This makes it reasonable to conclude that the method described here allows accurate elucidation of the
- 25 amino acid sequences that comprise antigenic determinants.

It was striking that all of the recombinant clones that contain coding sequences for an antigenic determinant express detectable levels of that

-26-

determinant. The design of the lambda gt11 system, coupling the expression of fusion protein with the use of lon protease-deficient host cells, may account in part for the ability to express all 5 encoded epitopes at detectable levels. The particular monoclonal antibodies used here and the segmental epitopes that they recognize might also influence this result.

These results attest to the power of the 10 approach used here to detect and isolate specific antigen-coding sequences from lambda gt11 recombinant DNA libraries. It is surprising that all but one of the 24 different anti-mycobacterial protein monoclonal antibodies assayed react with 15 antigen produced by lambda gt11 recombinant DNA clones Young, R.A. et al., Proceedings of the National Academy of Sciences, USA, 82:2583-2587 (1985); Young R.A., et al., Nature, 316:450-452 (1985). The signal-producing antibodies bind to 23 20 different epitopes in 12 different M. leprae and M. tuberculosis proteins. All of these antibodies produce signals on nitrocellulose blots of mycobacterial proteins transferred from SDS polyacrylamide gels, suggesting that they recognize continuous 25 antigenic determinants. Why the majority of monoclonal antibodies made against M. leprae proteins react with segmental determinants is unclear, but might reflect the presence of denatured protein in the mycobacterial antigen preparations used for 30 immunizing or hybridoma screening. Alternatively,

-27-

segmental portions of mycobacterial polypeptides may be more abundant or immunogenic than assembled topographic sites.

The set of 29 well characterized subclones that 5 served to delimit the six epitopes can be used to deduce antigenic determinants on the 65 kD molecule that are recognized by other antibodies or by T cell clones. A simple array permits rapid determination of the clones that produce polypeptides containing 10 the appropriate antibody epitope. These recombinant clones can also be used to elucidate determinants to which T cells respond; E. coli lysates containing antigen expressed by lambda gt11 recombinants can be used to assay antigen-specific T cell stimulation in 15 vitro. Mustafa, A.S. et al., Nature, 319:63-66 (1986).

III. Implications for Leprosy

The availability of well characterized M. 20 leprae antigens make it possible to address basic biochemical, immunological, diagnostic and therapeutic questions still unanswered about leprosy and M. leprae. For example, M. leprae specific antigenic determinants can be used to develop simple and specific seroepidemiological tests to screen 25 human populations (e.g., in areas where leprosy is endemic). The serological tests will be highly specific because of the use of an antigenic determinant known to be unique to M. leprae (i.e., that recognized by the MLIIIE9 monoclonal antibody).

-28-

For example, a serological test to detect the presence of antibody to M. leprae protein can make use of M. leprae protein or peptide (such as the unique antigenic determinant) immobilized on a solid phase to form an antigen-immunoadsorbent. The immunoadsorbent is incubated with the sample to be tested. After an appropriate incubation period, the immunoadsorbent is separated from the sample and the presence of antibodies to the M. leprae protein or peptide determined. This can be done, for example, by addition of labeled antibodies (e.g., enzyme labeled, radioactively labeled) to the mixture and determination of the amount of label associated with the immunoadsorbent. Particularly useful is the well known ELISA technique, in which the antigenic determinant unique to M. leprae can be used. Serological tests will make early diagnosis of leprosy feasible, thus permitting early treatment to reduce deformity of infected individuals and limiting transmission of the disease to others.

Resistance to leprosy is provided by cell-mediated immunity. The strategy used herein to define antibody binding sites can be extended to determine which segments of the antigen are recognized by M. leprae-specific T cells. A mixture of peptides recognized by helper T cells can provide a specific skin test antigen for use in assessing the immunological status of patients and their contacts. A mixture of such peptides in a solution can be administered by injection under the skin. Such a reagent is useful in evaluating rapidly the immunological efficacy of candidate vaccines being

-29-

developed. Bloom, B.R. and Mehra, V., in: New Approaches to Vaccine Development (R. Bwell and G. Torrigiana, ed.), Schwabe & Co., pp 368-389 (1984). In addition, peptides recognized by M. leprae-

5 specific T cells can be components of a vaccine against the disease.

A vaccine can be constructed by incorporating a gene encoding a protein or a peptide, such as an antigenic determinant, into an appropriate vector.

10 For example, the gene encoding the 65kD M. leprae protein or a portion of the protein can be incorporated into a recombinant vector such as vaccinia virus or bacteria (e.g., cultivatable mycobacteria such as BCG) to produce a vaccine
15 capable of conferring long-lasting cell-mediated immunity on individuals to whom it is administered.

Equivalents

Those skilled in the art will recognize, or be able to ascertain, using no more than routine 20 experimentation, many equivalents to the specific materials and components described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims.

-30-

CLAIMS

1. Isolated DNA encoding an immunodeterminant protein antigen of Mycobacterium leprae.
2. DNA of Claim 1 selected from the group consisting of DNA encoding Mycobacterium leprae protein antigens of molecular weight 65kD, 5 36kD, 28kD, 18kD and 12kD.
3. Isolated DNA encoding an antigenic determinant of Mycobacterium leprae protein.
- 10 4. DNA of Claim 3 which encodes an antigenic determinant selected from the group consisting of antigenic determinants of Mycobacterium leprae proteins of molecular weight 65kD, 36kD, 28kD, 18kD and 12kD.
- 15 5. Isolated DNA encoding an amino acid sequence of an antigenic determinant of Mycobacterium leprae protein, said protein having a molecular weight of approximately 65kD.
- 20 6. Isolated DNA of Claim 5 encoding an antigenic determinant unique to Mycobacterium leprae protein, said determinant being recognized by the monoclonal antibody MLIIIIE9.
7. Isolated DNA having the nucleotide sequence of Figure 1 or a portion of said sequence.

-31-

8. A peptide encoded by DNA having the nucleotide sequence of Figure 1 or by a portion of said nucleotide sequence.
9. A peptide having the amino acid sequence of an antigenic determinant of Mycobacterium leprae protein, said antigenic determinant being unique to Mycobacterium leprae protein.
5
10. A peptide of Claim 9 which has an amino acid sequence selected from the group consisting of:
 - a. NSLADAVKVTLGPKGKGRNVVLEKKWGAPTTNDGVS;
 - b. RNVAAGANPLGLKRGIEKAV;
 - c. ALDKLKLTGDEATGA;
 - d. GEYEDLLKAGVADP;
 - e. TRSALQNAASIAGLF; and
 - f. ASDPTGGMGGMDF.
- 15
11. A peptide encoded by a Mycobacterium leprae gene, said peptide being recognized by helper T cells.
12. A peptide encoded by the Mycobacterium leprae DNA insert of clone Y3178 or a portion of said DNA insert.
20
13. A vaccine comprising DNA encoding Mycobacterium leprae protein in a recombinant vaccine vector capable of expressing said DNA.

-32-

14. A vaccine of Claim 13 in which the recombinant vaccine vector is vaccinia virus or cultivatable mycobacteria.
15. A vaccine of Claim 14 in which the DNA encodes the 65kD Mycobacterium leprae protein or a portion of said protein.
16. A vaccine comprising DNA encoding an antigenic determinant unique to Mycobacterium leprae in cultivatable mycobacteria capable of expressing said DNA.
17. A vaccine of Claim 15 in which the DNA encodes an antigenic determinant of Mycobacterium leprae which is recognized by the monoclonal antibody MLIIIIE9.
- 15 18. A method of detecting antibody against Mycobacterium leprae in a biological fluid, comprising the steps of:
 - a) incubating an immunoadsorbent comprising a solid phase to which is attached immunodeterminant Mycobacterium leprae protein with a sample of the biological fluid to be tested, under conditions which allow the anti-Mycobacterium leprae antibody in the sample to bind to the immunoadsorbent;
 - 20 25 b) separating the immunoadsorbent from the sample; and

-33-

c) determining if antibody is bound to the immunoadsorbent as an indication of anti-Mycobacterium leprae in the sample.

19. A method of Claim 18 in which the Mycobacterium leprae protein attached to the solid phase has a molecular weight of 65kD.

5 20. A method of detecting antibody against Mycobacterium leprae in a biological fluid, comprising the steps of:

10 a) incubating an immunoadsorbent comprising a solid phase to which is attached a peptide having the amino acid sequence of an antigenic determinant of Mycobacterium leprae protein with a sample of the biological fluid to be tested, under conditions which allow antibody against Mycobacterium leprae to bind to the immunoadsorbent;

15 b) separating the immunoadsorbent; and

20 c) determining if antibody is bound to the immunoadsorbent as an indication of the presence of antibody against Mycobacterium leprae in the sample.

25 21. A method of Claim 20 in which the peptide has the amino acid sequence of an antigenic determinant which is unique to Mycobacterium leprae protein.

-34-

22. A method of determining the amino acid sequence of an antigenic determinant of a protein antigen, comprising the steps of:

- 5 a) fragmenting DNA encoding said protein antigen to produce random fragments;
- b) inserting said DNA fragments into an appropriate expression vector;
- c) cloning the expression vector containing said DNA fragments;
- 10 d) isolating cloned vectors expressing DNA fragments encoding an antigenic determinant by screening said cloned vectors with monoclonal antibodies specific for the antigenic determinant;
- 15 e) determining the nucleotide sequence of the DNA fragments contained in said isolated cloned vectors;
- f) determining the amino acid sequence common to said DNA fragments; and
- 20 g) deducing the amino acid sequence encoded by said common amino acid sequence.

FIG. 1

GAATTCCGGAATTGCACTCGCCTTAGGGGAGTGCTAAATGATCCTGGCACTCGCGATCA
 10 20 30 40 50 60
 V P G R D G E T Q P A S C G R P S R A
 GCGAGTGCCAGGTGGGACGGTGAGACCCAGCCAGCAAGCTGTGGTCGTCCGTGGGG
 70 80 90 100 110 120
 L H P A S V S N G G C R H P V T L A S F
 CACTGCACCCGGCCAGCGTAAGTAATGGGGTTGTGGCACCCGGTAGCTTCATT
 130 140 150 160 170 180
 L I R R N H F A M A K T I A Y D E E A R
 CCTAATCCGGAGGAATCACTTCGCAATGCCAAGACAATTGGGTACGACGAAGAGGCC
 190 200 210 220 230 240
 R G L E R G L ^AN S L A D A V K V T L G P
 GTGGGGCCTCGAGGGGCTTGAACAGCCTGGGGACGGTAAAGGTGACGTTGGTCC
 250 260 270 280 290 300
K G R N V V L E K K W G A P T I T H D G
 GAAGGGGCGAACGTCGTTCTAGAGAAGAAGTGGGTGCTCCACGATCACCAACGATG
 310 320 330 340 350 360
V S I A K E I E L E D P T E K I G A E L
 GCGTGTCCATGCCAAGGAGATCGAGCTGGAGGACCCGTACGAGAAGATTGGGCTGAGTT
 370 380 390 400 410 420
 V K E V A K K T D D V A G D G T T T A T
 GGTCAAGGAAGTCGCAAGAAGACAGATGACGTGGGGTGTGGCACCAACGACGGCCA
 430 440 450 460 470 480
V L A Q A L V K E G L R N V A A G A N P
 CGGTGCTGGCCAGGCATTGGTCAAAGAGGGCTACGCAACGTCGGCCGGCGCCAACCC
 490 500 510 520 530 540
L G L K R G I E K A V D K V T E T L L K
 GCTAGGTCTCAAGCGTGGCATCGAGAAAGCTGTGATAAGGTAAGTAACTGAGACTCTGCTCA
 550 560 570 580 590 600

SUBSTITUTE SHEET

FIG. 1 (CONT'D)

D A K E V E T K E Q I A A T A A I S A G
 AGGACGGCTAAGGAGGTCAAACCAAGGAACAAATTGCTGCCACTGCAGCGATTCGGCGGG
 610 620 630 640 650 660
 D Q S I G D L I A E A M D K V G H E G V
 TGACCAGTCGATCGGTGATCTGATCGCCGAGGGCATGGACAAGGTTGGCAACGAGGGTG
 670 680 690 700 710 720
 I T V E E S N T F G L Q L E L T E G M R
 TTATCACCGTCAAGGAATCCAACACCTTEGGTCTGCAGCTCGAGCTCACCGAGGGATGCG
 730 740 750 760 770 780
 F D K G Y I S G Y F V T D A E R Q E A V
 GTTCGACAAGGGCTACATTCGGGCTACTTCGTACCGACGCCAGCGTCAGGAAGCTG
 790 800 810 820 830 840
 L E E P Y I L L V S S K V S T V K D L L
 TCCTAGAGGAGCCCTACATCCTCTGGTCAGCTCCAAAGTGTACCGTCAAGGACCTGCT
 850 860 870 880 890 900
 P L L E K V I Q A G K S L L I I A E D V
 GCCGCTGCTAGAGAAGGTCACTCAGGCCGGCAAGTCGCTGCTGATCATTGCTGAGGATG
 910 920 930 940 950 960
 E G E A L S T L V V N K I R G T F K S V
 TCGAGGGTGAGGCCTGCTACCCCTGGTCAACAAGATCCGTGGCACTTCAGTCGGT
 970 980 990 1000 1010 1020
 A V K A P G F G D R R K A M L Q D M A I
 GGCGGTCAAAGCTCCTGGCTTGTCAGCGAGGCAATGTTGCAAGACATGGCCA
 1030 1040 1050 1060 1070 1080
 L T G A Q V I S E E V G L T L E N T D L
 TTCTCACCGGAGCCCAGGTCACTCAGCGAGGAGGTGGTCTCACATTGGAGAACACCGATCT
 1090 1100 1110 1120 1130 1140
 S L L G K A R K V V M T K D E T T I V E
 GTCAATTGCTGGCAAGGCCGGCAAGGTGGTATGACCAAGGACGAAACCAACCATCGTCG
 1150 1160 1170 1180 1190 1200

SUBSTITUTE SHEET

FIG. 1 (CONT'D)

G A G D T D A I A G R Y A Q I R T E I E
 AGGGTGCCGGTGACACCGACGCCATGCCGGCGAGTGGCTCAGATCCGTACCGAGATCGA
 1210 1220 1230 1240 1250 1260
 N S D S D Y D R E K L Q E R L A K L A G
 GAACAGTGACTCTGACTATGACCGCGAGAAACTGCAGGAACGCCCTGGCTAAGTTGGCCG
 1270 1280 1290 1300 1310 1320
 G V A V I K A G A A T E V E L K E R K H
 GTGGTGTTCGGTGATCAAGGCCGGTGCTGCCACTGAGGTGGAGCTCAAGGAGGCCAAGCA
 1330 1340 1350 1360 1370 1380
 R I E D A V R N A K A A A V E E G I V A G
 CCCCATCGAGGACGCAGTCCGCAACGCCAAGGCCGGTGGAGGAGGGGATCGTCGCCG
 1390 1400 1410 1420 1430 1440
 G G V T L L Q A A P^①A L D K L K L T G D
 CGGGCGGTGTGACTCTGCTACAGGCTGCTCCGGCTCTGGACAAGCTGAAGCTGACCGGTGA
 1450 1460 1470 1480 1490 1500
E A T G A N I V K V A L E A P L K O I A
 CGAGGCCACCGGTGCCAATATTGTCAAGGTGGCGTTGGAAGCTCCGCTCAAGCAGATCG
 1510 1520 1530 1540 1550 1560
 F N S G M E P G V V A E K V R N L S V G
 CCTTCATTCCGGGATGGAGCCCGGCGTGGTGGCCAAAAGGTGGTAACCTTCAGTGGG
 1570 1580 1590 1600 1610 1620
 H G L N A A A T^DG E Y E D E L K A G V A D
 TCACGGCCTGAACGCCGCCACGGTGAGTACGAGGACCTGCTCAAGGCCGGCTGGCG
 1630 1640 1650 1660 1670 1680
P V K V T R S A L Q N A A S I A G L F L
 ACCCGGTGAAGGTTACACGTTCTGCCGTGCAGAACGCCAGCGTCCATGCCGGCTGTTCT
 1690 1700 1710 1720 1730 1740
 T T E A V V A D K P E K T A A P^②A S D P
 TACTACGGAGGCCGTGCTGCCGACAAGCCGGAGAAGACGGCAGCTCCGGCGAGCCACC
 1750 1760 1770 1780 1790 1800

SUBSTITUTE SHEET

FIG. 1 (CONT'D)

T	G	G	M	G	G	M	D	F
CGACCCGGTGGCATGGGTGGTATGGACTTCTGACGTCCGGTCATGATGCAGGTAGCTACGTG								
1810	1820	1830	1840	1850	1860			
GTCTGAAGTGGGGTACTTCATCAACTGAGTAGCGGCCGGCGAACCTGGACAATCGAATT								
1870	1880	1890	1900	1910	1920			
GGAGTTGACAAAGAAAAAGAGCCCCGGCCCCCAAAAAAAAGGGACCAGGGCTCTTCTTGTTC								
1930	1940	1950	1960	1970	1980			
TTGGCGGTCCAGGGGAGTCGGGCTTGGCCTCGAGGTGCAGGAGCGTGGGTCCGAACGAC								
1990	2000	2010	2020	2030	2040			
ACTGAACCGGGCAGTCGTTCCGGGGCTCGCTCGTGCCTGGAAAGGAGCGCGCGCGC								
2050	2060	2070	2080	2090	2100			
CCGAGCCGTTCTAGGGTGTTGTGGGTGTTCATAGGTGGTGGGTGAAATGGCTGTTTT								
2110	2120	2130	2140	2150	2160			
GCGTTTATGACTGGCCGATATGTTGGTAGTCGTGGGGGGCAGCCCGGAATCCTGTTGAC								
2170	2180	2190	2200	2210	2220			
GTGTTTGCTGTGTTGCCGGTTTGTGGTGGCTGACTGCCTGCTTCTGATGA								
2230	2240	2250	2260	2270	2280			
GGCTTCGTGCTTTGCCGCAGTGGACACGATTAGCGCGGCCACGTAAGCATGTCGGTGG								
2290	2300	2310	2320	2330	2340			
TGGGTGCTGTTGGTCTACATGTTGATGATGCCAGGGGCTGGGCACCTGGGCTGTGCTG								
2350	2360	2370	2380	2390	2400			
AAGGCGATATCGATGCAGGGCGTGGGTGTGAGGGTAGTTGTTAGCGCCGGGGGTAGGGGC								
2410	2420	2430	2440	2450	2460			
GTTTTAGTGTGCATGTCATGGCCTTGAGQTGTGGCGTGGTCAATGTGGCCGCACCTGAA								
2470	2480	2490	2500	2510	2520			

SUBSTITUTE SHEET

FIG. 1 (CONT'D)

CAGGCACGTCCCCGTGCACGGTATAACTATTGCACCTGATGTTATCCCTTGACCCATT
2530 2540 2550 2560 2570 2580
CTGCCGCTGGTATCGGTGTCGGCGGCTTGTGACCGGCCCTCAGCCAGCAAGCAGGCATG
2590 2600 2610 2620 2630 2640
CCGGCGGGTGCAGCAGTATCGTGTAGTGAACAGTGCATCGATGATCCGGCCGTCGGCGG
2650 2660 2670 2680 2690 2700
CACATACGGCAACCTCTAGCGCAGATCAACCACCCACACCCCACCAAGCCCACCAACA
2710 2720 2730 2740 2750 2760
CCACCAACCAAACCAAACAGCAAAAAATAACCACCAAATGACCATCACGACGACGGATAT
2770 2780 2790 2800 2810 2820
GGTGGGTGCGTTAGCGCGCAGATGCCGCTGCCGCCGATAGCAACCCGGTTGGGATCA
2830 2840 2850 2860 2870 2880
ACGCTGTGTTGGGCACTAGCAGGTTAGAGTAGGCTGAGGCTAGCGCAATCGCAGT GAGA
2890 2900 2910 2920 2930 2940
GATCTGGTGCCGGATCGGTTAACCGCATGCCGTACGGTAAAAGATAAGACGTTATTGA
2950 2960 2970 2980 2990 3000
CCGGCATGCTCTAGTTGGTTGTGTTTCCAGGGCGGTGGTGGCTATAGCTGCCCGGGCG
3010 3020 3030 3040 3050 3060
TGTGTCGATCCTGTTGATGACACGGCGCGCGAGCCACTAATATGGCGTTGCCAATAGCG
3070 3080 3090 3100 3110 3120
TCTGGATCTCGCCGATGAGTGGTTGCTTCCCTCCACCCAGTGTATCGTATCGCAGTAC
3130 3140 3150 3160 3170 3180
CGGCTACCGGTGTTGGCCGCTGATTGATTGAAGAAAAGGTTCAATGGATCGGCAACGTC
3190 3200 3210 3220 3230 3240

FIG. 1 (CONT'D)

GTCGATTCCGTCGTACGGAAACACTCGACTTTGTCACTTGTGGGTGGCTCCG
3250 3260 3270 3280 3290 3300
AATTGATTCTTGACGTCCCGGACCGTCTGCATCGGGTAGTTGTGATTTCTGGGAATG
3310 3320 3330 3340 3350 3360
CAGCACTACGTGACCGAGGTGTTGAGCGAGTACGGCCTGGCGATGGACCCGTCTTGGT
3370 3380 3390 3400 3410 3420
GACATGTCCGACCAGAACATCAACGCAACTACCGTTGGCTTGGCTTGGCGTCTGGTGTAA
3430 3440 3450 3460 3470 3480
CGGCCACGTACTTGGGTGCCACCAACCGGTGATTCGTGGCTTGGTGAATGGCCATGGT
3490 3500 3510 3520 3530 3540
TCCACTGAGGCCGGTGCTGCTCAGCGCAGACAGACCATCACGACGTGGCCCAGCACGGTGT
3550 3560 3570 3580 3590 3600
GCAGGTGAAATC
3610

SUBSTITUTE SHEET

7/11

FIG. 2



**SUBSTITUTE SHEET**

FIG.3


65K

1 kb



36K

Y3180



28K

Y3158
Y3163
Y3184
Y3167




18K

Y3179
Y3181
Y3182
Y3183




12K

Y3184
Y3191




SUBSTITUTE SHEET

FIG.4



SUBSTITUTE SHEET

FIG. 5



SUBSTITUTIVE SPICES

FIG. 5 (CONT'D)

Clone	Start	End	C1-1	MLIIH9	MLIIIe9	MLIIIC8	T2.3	MLIIIC8
Y3194	2	733	+	+	-	-	-	-
Y3225	55	12	+	+	-	-	-	-
	37	418						
Y3203	47	622	+	+	-	-	-	-
Y3223	56	367	+	+	-	-	-	-
Y3196	68	725	+	+	-	-	-	-
Y3233	89	576	+	+	-	-	-	-
Y3199	135	-740	+	+	-	-	-	-
Y3201	1014	162	+	+	-	-	-	-
Y3198	1170	163	+	+	-	-	-	-
Y3202	227	743	+	+	-	-	-	-
Y3222	251	631	+	+	-	-	-	-
Y3243	263	803	+	+	-	-	-	-
Y3246	503	875	+	+	-	-	-	-
Y3244	514	-820	+	+	-	-	-	-
	-2830	3203						
Y3218	882	2008						
Y3211	-1070*	1517						
Y3219	1202	1525						
Y3234	-1280	1785						
Y3240	1286	1775						
Y3237	1300	1884						
Y3217	1369	1352						
	1363	1591						
Y3206	1400	1690						
Y3210	1473	1739						
Y3186	1548	1711						
Y3185	1575	1684						
Y3189	1644	1850						
Y3187	1677	1868						
Y3239	1694	1783						
	3511	3603						
Y3192	1790	1853	+	-	-	-	-	+
Y3178	1	3613	+	+	+	+	+	+

SUBSTITUTE SHEET

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ : C12N 15/00, G01N 33/569 A61K 39/04		A2	(11) International Publication Number: WO 88/00974 (43) International Publication Date: 11 February 1988 (11.02.88)
<p>(21) International Application Number: PCT/US87/01825 (22) International Filing Date: 28 July 1987 (28.07.87) (31) Priority Application Number: 892,095 (32) Priority Date: 31 July 1986 (31.07.86) (33) Priority Country: US</p> <p>(71) Applicant: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH [US/US]; Nine Cambridge Center, Cambridge, MA 02142 (US). (72) Inventor: YOUNG, Richard, A. ; 11 Sussex Road, Winchester, MA 01890 (US). (74) Agents: GRANAHAN, Patricia et al.; Hamilton, Brook, Smith & Reynolds, Two Militia Drive, Lexington, MA 02173 (US).</p>		<p>(81) Designated States: AT (European patent), AU, BE (European patent), BR, CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>	

(54) Title: GENES ENCODING ANTIGENS OF *M. LEPRAE*

(57) Abstract

Genes encoding five immunodeterminant protein antigens of the leprosy parasite *Mycobacterium leprae* have been isolated. The gene encoding the *M. leprae* 65kD antigen was sequenced and a lambda gt11 gene sublibrary was constructed with fragments of the gene. Recombinant DNA clones producing specific antigenic determinants were isolated using monoclonal antibodies and the sequences of their insert DNAs were determined with a rapid primer extension method. Amino acid sequences for six different epitopes of the *M. leprae* protein were elucidated. A peptide containing sequences for one of these epitopes, which is unique to *M. leprae*, was synthesized and shown to bind the appropriate monoclonal antibody. The approach described here can be used to elucidate rapidly protein epitopes that are recognized by antibodies or T cells. In addition, the well-characterized *M. leprae* antigens can be used in prevention, diagnosis and treatment of leprosy.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT Austria
AU Australia
BB Barbados
BE Belgium
BG Bulgaria
BJ Benin
BR Brazil
CF Central African Republic
CG Congo
CH Switzerland
CM Cameroon
DE Germany, Federal Republic of
DK Denmark
FI Finland

FR France
GA Gabon
GB United Kingdom
HU Hungary
IT Italy
JP Japan
KP Democratic People's Republic
of Korea
KR Republic of Korea
LI Liechtenstein
LK Sri Lanka
LU Luxembourg
MC Monaco
MG Madagascar

ML Mali
MR Mauritania
MW Malawi
NL Netherlands
NO Norway
RO Romania
SD Sudan
SE Sweden
SN Senegal
SU Soviet Union
TD Chad
TG Togo
US United States of America

-1-

Genes Encoding Antigens of *M. leprae*

Description

Background

Leprosy is a chronic infectious disease
5 afflicting millions of people worldwide. The overwhelming majority of leprosy cases occur in Third World countries. Approximately 3000 leprosy cases now exist in the United States and an average of 225 new cases are reported annually, almost all
10 in recent immigrants from areas where leprosy is endemic.

The disease is caused by the obligate intra-cellular parasite Mycobacterium leprae (*M. leprae*), which is found in monocytes, macrophages, epithelial
15 cells and, occasionally, peripheral nerve Schwann cells. The mechanism by which *M. leprae* is transmitted is as yet unknown and the time elapsing between infection with the organism and appearance of clinical symptoms can be as long as 10 years,
20 during which time many others can unknowingly become infected.

-2-

Leprosy is a disease which presents a spectrum of diverse clinical and immunological manifestations. At one end of the spectrum are tuberculoid leprosy patients, who develop high levels of specific cell-mediated immunity, which ultimately kills and clears the bacilli in the tissues. Immunohistochemical studies have identified the predominant infiltrating lymphocytes as T4 helper cells. Peripheral nerve damage occurs concomitant with clearing of the bacilli in tuberculoid leprosy, and is thought to be immunologically mediated.

At the opposite end of the spectrum, lepromatous patients exhibit a selective unresponsiveness to antigens of M. leprae and the organisms often multiply to extraordinary numbers (e.g., $10^{10}/\text{cm}^2$ skin). Infiltrating lymphocytes are predominately of the T8 suppressor type. Peripheral nerve damage also occurs in lepromatous leprosy, although the mechanism of the damage is not clear. The majority of leprosy patients fall between these two extremes in the spectrum and are classified as borderline tuberculoid, borderline, or borderline lepromatous.

Because M. leprae attacks the nerve cells of the skin and peripheral nervous system, a loss of sensation and, in some cases, loss of control over muscles occurs in the extremities. As a result, leprosy victims often do not feel pain, and injuries to hands, arms, legs and feet are not noticed and

-3-

frequently go untreated. Such wounds become infected; formation of scar tissue and scabs follows. Repeated injury results in gradual deformation and destruction of tissues.

5 A method of detecting the disease at an early stage would make it possible to screen populations in areas where the disease is common and begin treatment at an early stage in those affected, thus preventing nerve damage and deformity in the af-
10 fected individual and limiting its transmission to others. Such a method is not available and diag-
 nosis is presently delayed until clinical signs of the disease appear. Treatment of leprosy patients is not highly successful, particularly because M.
15 leprae is becoming resistant to dapsone, the most widely used anti-leprosy drug. As many as 50 percent of new leprosy patients in some Asian clinics have drug-resistant leprosy.

As with other intracellular parasites, protec-
20 tive immunity against M. leprae is dependent on T cells and cell mediated immunity. Bloom, B.R. and T. Godal, Review of Infectious Diseases, 5:765-780 (1983). The human immune response to M. leprae has been shown to involve both T_4 and T_8 cells, which
25 are thought to be involved in T cell help and T cell suppression, respectively. Little is known about the importance of individual M. leprae antigens for immune protection and/or suppression. It has been shown that T_4 cells from sensitized individuals are
30 stimulated in vitro by crude M. leprae protein